These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31471269)

  • 1. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review.
    Yildirim N; Gonen M; Balgetir F; Er MB
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1104-e1107. PubMed ID: 31471269
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
    Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
    Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
    Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
    Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
    Beulque Y; Deleu AL; Punie K; De Wever L; Baldewijns M; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Oct; 17(5):e909-e912. PubMed ID: 31378579
    [No Abstract]   [Full Text] [Related]  

  • 6. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
    Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
    Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
    Osmán-García I; Congregado-Ruiz CB; Lendínez-Cano G; Baena-Villamarin C; Conde-Sanchez JM; Medina-López RA
    Urol Int; 2020; 104(3-4):323-326. PubMed ID: 31914452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
    Bednarek R; Marks K; Lin G
    Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
    Grimaux X; Delva R; Jadaud E; Croue A
    Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
    [No Abstract]   [Full Text] [Related]  

  • 10. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.
    Mathew Thomas V; Bindal P; Ann Alexander S; McDonald K
    J Oncol Pharm Pract; 2020 Mar; 26(2):459-461. PubMed ID: 30909794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.
    Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T
    Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced lichen planus.
    Yilmaz M; Mese SG; Celik U
    J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
    Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma.
    Yu-Li Su H
    Clin Genitourin Cancer; 2018 Apr; 16(2):114-116. PubMed ID: 29329663
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
    Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
    J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute demyelinating polyneuropathy induced by nivolumab.
    Fukumoto Y; Kuwahara M; Kawai S; Nakahama K; Kusunoki S
    J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):435-437. PubMed ID: 28844069
    [No Abstract]   [Full Text] [Related]  

  • 20. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.